SEC Form 4Coverage since Jun 4, 2026
$PCRX insider trading
Over the last 12 months, Pacira BioSciences insiders reported no purchases and 2 sales totaling $372K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $372K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $PCRX · 12Mvia TradingView
Top insiders · 12m
RIKER LAURENSenior Vice President, Finance1× · $144K
WILLIAMS KRISTENChief Administrative Officer1× · $228K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | RIKER LAURENSenior Vice President, Finance · O | ▼ Sale | 6,115 | $23.5 | $144K | -8.9% | plan |
| Jun 4, 2026 | WILLIAMS KRISTENChief Administrative Officer · O | ▼ Sale | 10,259 | $22.27 | $228K | -5.8% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PCRX feed.